Compare · ICCC vs QDEL
ICCC vs QDEL
Side-by-side comparison of ImmuCell Corporation (ICCC) and QuidelOrtho Corporation (QDEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCC and QDEL operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- QDEL is the larger of the two at $700.5M, about 6.7x ICCC ($103.8M).
- ICCC has been more active in the news (5 items in the past 4 weeks vs 4 for QDEL).
- QDEL has more recent analyst coverage (19 ratings vs 0 for ICCC).
- Company
- ImmuCell Corporation
- QuidelOrtho Corporation
- Price
- -
- -
- Market cap
- $103.8M
- $700.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1987
- News (4w)
- 5
- 4
- Recent ratings
- 0
- 19
ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
QuidelOrtho Corporation
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Latest ICCC
- President and CEO Te Boekhorst Paul Francis Olivier exercised 16,393 shares at a strike of $6.10, increasing direct ownership by 92% to 34,131 units (SEC Form 4)
- SEC Form 10-Q filed by ImmuCell Corporation
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026
- SEC Form S-8 filed by ImmuCell Corporation
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026
- SEC Form 8-K filed by ImmuCell Corporation
- ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
- SEC Form 10-Q filed by ImmuCell Corporation
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
Latest QDEL
- SEC Form SCHEDULE 13G filed by QuidelOrtho Corporation
- QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- QuidelOrtho Reports Third Quarter 2026 Financial Results
- Transforming Data Into Actionable Insights in the Lab
- QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026
- SEC Form 4 filed by QuidelOrtho Corporation
- QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation
- QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
- Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment